Join
Live feed
·
PRReleasevia Quantisnow
Alector Inc. logo

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

ByQuantisnow·Wall Street's wire, on your screen.
ALEC· Alector Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALEC (Alector Inc.) and more on Quantisnow.